Sciconx is a leading conference organizer that helps you explore the future challenges of your industry and find innovative solutions. We connect you with the best speakers from around the world who have the expertise and experience to inspire and guide you. We also facilitate ideation sessions where you can design and validate new ideas with your end users. Whether you need a keynote, a workshop, or a panel discussion, we can help you find the right speaker for the right audience at the right time.
Our webinars are thoughtfully designed to deliver value to a wide range of individuals. Whether you're looking to grow your skills, explore new opportunities or gain insights from experts, here's who will benefit most from attending:
Professionals Seeking Growth
Academics and Researchers
Entrepreneurs and Business Owners
Students and Lifelong Learners
Industry Enthusiasts
In a world where knowledge is power, webinars have emerged as one of the most accessible and impactful ways to learn, grow and connect. Don't miss the chance to learn, grow and connect in ways that truly matter.
Learn from the Best
Stay Updated with Trends
Flexible and Convenient Learning
Interactive Experience
Expand Your Network
Cost-Effective Knowledge
Access to Exclusive Content
Inspiration and Motivation
Tailored for Your Needs
Be Inspired
Registering for a webinar is essential to gain access to the unique opportunities and secure a chance to grow, connect and gain insights that can drive your personal and professional success. Webinars are more than just online meetings, they're gateways to knowledge, innovation, and growth.
Pharmaceutical companies are often lambasted for rising drug costs. For example, the price of new drugs entering the US market in 2023 was 35% higher than in 2022. According to an analysis from Reuters, part of the increase is due to a move to develop therapies for rare diseases: because fewer people have those condition, drug makers push up the per-dose price to recover their costs. But the cost of developing drugs for more common diseases, including cancers, is also rising rapidly.
AstraZeneca's planned £450 million investment in a new flu vaccine facility in Speke, Liverpool, has encountered setbacks due to delays in securing government support. Despite urgent warnings from the UK chairman to Business Secretary Jonathan Reynolds after Labour's election victory, early assurances regarding the government's advanced manufacturing plan were not provided promptly. Consequently, the project's timelines were affected, necessitating reworking to meet tight launch projections. The delays have led to frustration with the Whitehall process. The company had been seeking incentives and support to proceed with the investment. With AstraZeneca's significant contribution to the UK's life sciences sector and economy—being the largest private sector investor in UK R&D and employing around 8,700 people—the delays have put pressure on the government to secure private sector investment for economic growth. The government asserts its commitment to supporting innovative medicine development and is in active discussions with AstraZeneca.
A recent study highlights the transformative potential of artificial intelligence (AI) and large language models (LLMs) in the pharmaceutical industry. AI applications span various operational areas, including research and development, clinical trials, production, regulatory affairs, and quality control. Machine learning algorithms, in particular, are contributing to advancements in drug discovery and development, offering promising avenues for innovation and efficiency.
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park) announced on February 14 that it recently unveiled Countmate, a fully automated vial dispensing machine tailored to the unique preferences of the Canada and US market. Unlike Korea, where medications are commonly dispensed in pouch form, the pharmaceutical industry in Canada and US predominantly relies on the vial method, which involves packaging drugs in plastic bottles. With the launch of Countmate, Hanmi aims to strengthen its presence in the region and drive significant growth in its global sales.
The Indian pharmaceutical and healthcare industry has played a stellar role in the fight against COVID-19 during the pandemic. From managing the supply chain of nearly two billion vaccine doses in the country, to ensuring seamless vaccine shipments to over 100 nations, supply chains have been at the forefront of the battle against the pandemic. However, the pharmaceutical industry faced significant challenges too such as medicine stock-outs, last-mile service delivery issues, ill-equipped warehousing facilities, shortage of qualified labour etc.
South Korea allocated 5.2% of its GDP to R&D in 2024.
Increasing public and private research and development (R&D) investments are expected to strengthen global leadership of Asia-Pacific's developed markets in the pharmaceutical sector, according to BMI.
Governments in developed markets such as Mainland China, Japan, and South Korea are increasing investments to foster an innovative life sciences ecosystem.